FDA Approves Nelkarmi for ALK-TKI-Resistant NSCLC
ALK-positive non-small cell lung cancer is driven by ALK gene fusions,accounting for about 3%–5%of NSCLC,often in younger patients with little or no smoking history.ALK TKIs such as crizotinib,alectinib,brigatinib,and lorlatinib improve outcomes,but resistance emerges over time through kinase-domain mutations,compound alterations,and CNS progression.
Nelkarmi(neladalkib,formerly NVL-655)is a next-generation oral,brain-penetrant,ALK-selective inhibitor designed to address single and compound resistant ALK mutations while sparing TRK to reduce off-target toxicity.Originally developed by Nuvalent,it was granted FDA accelerated approval on November 17,2026 for two adult populations:
unresectable locally advanced or metastatic disease previously treated with alectinib alone and progressed;
or disease progressed after at least two ALK TKIs and platinum-based chemotherapy.
It is not a first-line universal option;its role is post-ALK-TKI sequencing therapy.
The approval rests on ALKOVE-1(NCT05384626),a multicenter,open-label,single-arm phase 1/2 study with 222 evaluable patients:
post-alectinib cohort(67 patients):ORR 49%,with 76%of responders lasting≥6 months and 52%≥12 months;
heavily pretreated cohort(155 patients,≥2 ALK TKIs+platinum chemo):ORR 32%,with 69%of responders lasting≥6 months and 51%≥12 months.
Intracranial activity was also observed in patients with baseline CNS metastases,supporting its blood-brain-barrier penetration.
Dosing:150 mg orally once daily,with or without food,until progression or unacceptable toxicity.
Common adverse events:hepatotoxicity,musculoskeletal pain,constipation,dysgeusia,peripheral neuropathy,edema,fatigue.
Key monitoring:liver and renal function,CPK,and ocular examinations.Hold,reduce,or discontinue on severe hepatic injury,marked CPK rise with myalgia,or visual/corneal changes.Embryo-fetal toxicity requires effective contraception in patients with reproductive potential.
Clinically,Nelkarmi adds a structured next step after alectinib or multiline ALK-TKI failure,especially where lorlatinib options are limited.The approval is based on response and durability;confirmatory trials will further define overall survival and long-term benefit.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)